3. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmology. 2006;90(3): 262-267
  4. SCHOFF, E. O. et al. Estimated incidence of open-angle glaucoma Olmsted County, Minnesota. Ophthalmology, Philadelphia, v. 108, n. 5, p. 882-6, May 2001
  5. LEE, P. P. et al. Cost of patients with primary open-angle glaucoma. A retrospective study of commercial insurance claims data. Ophthalmology, v. 114, n. 7, p. 1241-7, July 2007b.
  6. Direção-Geral da Saúde. Classificação Internacional de Funcionalidade, Incapacidade e Saúde (2004) [Internet]. Portugal [Acedido no dia 19 de março 2017]. Disponível em:
  7. Office of Disease Prevention and Health Promotion. Healthy People 2020. Vision. (Abril 2016) [Internet]. EUA [Acedido no dia 19 de março de 2017]. Disponível em:
  8. Magalhães A. A Ambliopia: Um problema de saúde pública. Documentos de trabalho para um Plano Nacional de Saúde da Visão (2016). Portugal.
  9. KASS, M. A. et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmology, Chicago, v. 120, n. 6, p. 701-13, June 2002
  10. Leske M, Heijl A, Hussein M, et al. Early Manifest Glaucoma Trial. Factors for glaucoma progression and the effect of treatment. The early manifest glaucoma trial. Arch Ophthalmology.2003:12(1):48-56
  11. LEE, P. P. et al. Glaucoma in the United States and Europe. Predicting costs and surgical rates based upon stage of disease. Journal of Glaucoma, Philadelphia, v. 16, n. 5, p. 471-8, August 2007a.
  12. RYLANDER, N. R.; VOLD, S. D. Cost analysis of glaucoma medications. American Journal of Ophthalmology, New York, v. 145, n. 1, p. 106-13, Jan. 2008
  13. LEE P. P. et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Archives of Ophthalmology, Chicago, v. 124, n. 1, p. 12-19, Jan. 2006. Rev. APS, v. 11, n. 4, p. 444-450, out. / dec.. 2008
  14. BURR, J.M. et al. The clinical effectiveness and cost-effectiveness of screening for open-angle glaucoma: a systematic review and economic evaluation. Health Technology Assessment, Winchester, v. 11, n. 41,190, Oct.2007.
  15. TRAVERSO, C. E. et al. Direct costs of glaucoma and severity of the disease: a multinational long-term study of resource utilization in Europe. British Journal of Ophthalmology, London, v. 89, n. 10, p. 1245-9, October 2005.
  16. SCHMIER, J, K. al, The economic implications of glaucoma: a literature review. Pharmacoeconomics, Auckland, v.25, n 4, p.287-308,Apr.2007.
  17. LAFUMA, Aet al. Non-medical economic consequences attributable to visual impairment. A nation-wide approach in France Eur J Health Econ, ,7 ,n 3, p158-64,September ver 2006.
  18. DOSHI, A.; SINGH, K. Cost-effective evaluation of the glaucoma suspect. Current Opinion in Ophthalmology, Philadelphia, v. 18, n. 2, p. 97-103, Mar. 2007
  19. [3] VIANNA, C. M. M.; CAETANO, R. Avaliação tecnológica em saúde: introdução a conceitos básicos. Rio de Janeiro: UERJ, 2001, 33p.
  20. PRZYBYLSKI, K.G. et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacoterapy;  v.17, n.2, p.271-6, 1997
  21. FINKLER, S. A. The distinction between cost and charges. Annals of Internal Medicine, Philadelphia, v. 96, n. 1,p. 102-9, Jan.1982.
  22. DRUMMOND, M.F., et al. In Methods for economic evaluation of health care programs. 2nd edition. Oxford Medical Publications, 1997, UK.
  24. Paletta G. R, Paletta G. VM, Freitas SM, Chaoubah A.. Does de type of treatment have an influence on utility values in glaucoma population? Clin. OPHTALMOL 2015. 0: 1645-50.
  25. IG Stillitano et al. Economic impact of eye drop cost in glaucoma treatment. Arq. Bras Oftlamol.2005.68(1):79-84
  26. Kobelt G, Jönsson L, Gerdtham U, Krieglstein GK. Direct costs of glaucoma management following initiation of medical therapy. A simulation model based on an observational study of glaucoma treatment in  Germany. Graefes Arch C. Ophthalmol.1998;236(11):811-21.
  27. Hommer A, Wickstrom J, Friis MM, Steeds C, Thygesen J, Ferreras A, et al. A cost-effectiveness analysis of fixed-combination therapies in patients with open-angle glaucoma a European perspective. Curr Med Res Opin. 2008;24(4):1057-63
  28. Martínez A, Slof J. [Cost-efficacy analysis of fixed combinations of prostaglandin/ prostamide for treating glaucoma. Arch Soc Esp. Oftalmol. 2008;83(10):595-600. Spanish.
  29. Stein JD, Kim DD, Peck WW, Giannetti SM, Hutton D W. Cost-efffectiveness of medications compared with laser trabeculoplasty in patients with newly diagnosed open-angle glaucoma. Arch Ophthalmol. 2012 Apr; 130(4). 497-505.
  30. Miguel A., Azevedo L., Andrês R. Henriques F. , Lopes N., Rito F., Silva J F. Custo do Glaucoma em Portugal  ( 2012), Oftalmologia Suplemento Nº 1 Vol. 36: 29-32
  31. STWEWART, al. Cost-effectiveness of treating ocular hypertension. Ophthalmology, v.115. n. 1. p .94-8, January 2008
4ª Edição - Maio 2017